Water Tower Research Publishes Initiation of Coverage Report on Filament Health Corp. Titled, “Pioneer in Botanical Psychedelics Drug Development”

October 31, 2023, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on Filament Health Corp. (NE: FH) titled, “Pioneer in Botanical Psychedelics Drug Development”. The report can be accessed here.

Stewarded by a leadership team steeped in the expertise of botanical extraction, Vancouver-based Filament Health Corp. (NEO:FH/OTCQB: FLHLF/FSE:7QS) has developed a platform of proprietary technology to create psychedelic botanical drugs with unique IP advantages as well as some unique clinical advantages over generic synthesized single compound traditional drug preparations. The IP advantages stem from the difficulty of genericizing complex mixtures protected by process patents and trade secrets. Furthermore, the existence of a vast body of documented traditional knowledge obviates the need for preclinical studies and thereby accommodates Filament with a faster track to clinical development than synthetic drug developers. With the clinical trial landscape in psychedelics dominated by synthetically manufactured drug candidates, Filament can count itself as the first and only company that has naturally derived psychedelic compounds in clinical trials.  

Filament’s business model offers two principal pathways to potential revenue generation. One is via the potential commercialization of the company’s internal drug discovery and development programs, which are focused on the high unmet need of substance use disorders. The other is via the out-licensing its drug technology to third-party drug developers for their clinical developments targeting indications that are outside the company’s core focus. This strategy allows Filament to generate more immediate, pre-commercialization revenues as well as the potential to receive a more consistent flow of revenues should these drugs be approved and proceed to commercialization.

As part of its financial strategy, Filament has agreed to merge with SPAC Jupiter Acquisition Corp (NASDAQ:JAQC). The merger will result in an uplisting to the NASDAQ exchange through which it should allow it greater access to the capital markets for funds to support its drug development programs.

About Water Tower Research 

Water Tower Research is modernizing Investor Relations through research-driven communications and Investor Engagement. Sound investment research begins with good information. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor relations platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight to a new digital world of investor communications and engagement. Our research and investor content is distributed across traditional research aggregators like Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies take control of their IR program and proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients’ businesses, industries, and the investment opportunities they present.

Tags: Substance Abuse Disorders, Botanical, Clinical Trials, drug development, pharmaceuticals